Retrospective comparison between COBE SPECTRA and SPECTRA OPTIA apheresis systems for hematopoietic progenitor cells collection for autologous and allogeneic transplantation in a single center.

Introduction COBE SPECTRA [COBE] (Terumo, BCT Lakewood CO) apheresis system has been the most used device for hematopoietic progenitor cells (HPC) collection. Recently, it has been replaced by the SPECTRA OPTIA [OPTIA] (Terumo, BCT Lakewood CO) apheresis system. The aim of our study is to compare both methods for HPC collection. Material and methods We retrospectively compared 302 HPC collection apheresis procedures (115 allogeneic donors and 187 autologous). The study cohort was divided according to the apheresis system used to analyze the differences between COBE and OPTIA, specifically efficacy of apheresis procedure and product characteristics. Results OPTIA collections result in a higher CD34(+)collection efficiency in both groups (autologous 45.3% vs 41%,P < .006; allogeneic 54.9% vs 45%,P < .0001). The total of CD34(+)cells x10(6)/kg recipient collected in the product were comparable in both groups (autologous 2.9 in OPTIA group vs 2.8 in COBE group,P= .344; allogeneic 6.2 in OPTIA group vs 5.8 in COBE group,P= .186). The percentage of platelet loss in autologous donors was significantly lower (35.7% vs 40.8%,P < .01). Regarding quality of the product, we observed a significantly lower hematocrit in products collected with OPTIA in both groups (1.8% vs 4%,P < .0001) as well as significantly lower amount of leukocytes (median 153.4 vs 237.2 x 10(9)/L in autologous,P < .0001; 239.5 vs 340.2 x 10(9)/L in allogeneicP < .0001). Conclusion Both apheresis systems are comparable in collection of hematopoietic progenitor cells, with significantly higher collection efficiency with the OPTIA system. Collection products obtained with OPTIA contain significantly lower hematocrit and leukocytes.